An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors by Neda Stjepanovic, Amit M Oza, Anna Spreafico, Stephanie Lheureux, Marcus O Butler, Pamela S Ohashi, Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, Ben Wang, Shu Yi Shen, Ilias Ettayebi, Charles A Ishak, Philippe L Bedard, Albiruni Abdul Razak, Aaron R Hansen, Dave Cescon, Brendan Van As, Sarah Boross-Harmer, Lisa Wang, Trevor J Pugh, Lillian L Siu, Daniel D De Carvalho

Get full text